

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	Sirtuin 1 (SIRT1)	<p><i>In vitro</i> and mouse studies suggest inhibiting SIRT1 could increase the efficacy of Gleevec imatinib in CML. In CML cell lines, imatinib plus a SIRT1 inhibitor decreased cell growth and increased imatinib-induced apoptosis compared with either treatment alone. In mice receiving BCR-ABL tyrosine kinase-transformed bone marrow cells, those receiving <i>Sirt1</i>^{-/-} cells had delayed development of CML and increased survival compared with those receiving <i>Sirt1</i>^{+/+} cells. Next steps include developing a SIRT1 inhibitor.</p> <p>Elixir Pharmaceuticals Inc. has a SIRT1 inhibitor in preclinical testing to treat Huntington's disease (HD).</p> <p>Novartis AG markets Gleevec to treat CML and gastrointestinal stromal tumors (GISTs).</p> <p>SciBX 5(3); doi:10.1038/scibx.2012.71 Published online Jan. 19, 2012</p>	Patent application filed covering SIRT1 inhibition to treat cancer chemoresistance; available for licensing	Yuan, H. <i>et al. Blood</i> ; published online Dec. 29, 2011; doi:10.1182/blood-2011-06-361691 Contact: WenYong Chen, City of Hope, Duarte, Calif. e-mail: wechen@coh.org